ALBIO Share Price Performance
€1.21
-2.62 (-68.41%)
Price €1.21
Share Price€1.21
ALBIO Community Narratives
There are no narratives available yet.
Recent ALBIO News & Updates
No updates
Biosynex SA Key Details
Last Reported Earnings
Dec 31, 2024
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -2.31
- Gross Margin
- 56.76%
- Net Profit Margin
- -42.83%
- Debt/Equity Ratio
- 76.2%
Biosynex SA Competitors
About ALBIO
- Founded
- 1993
- Employees
- 476
- CEO
- WebsiteView website
Biosynex SA designs, manufactures, and distributes rapid diagnostic tests in France and internationally. The company offers medical devices for in vitro diagnosis in the form of rapid diagnostic tests, immunoblots, molecular biology, and point of care products for screening, diagnosis, and prevention in the areas of bacteriology, parasitology, mycology, virology, biochemistry and oncology, and women’s health, as well as COVID-19 tests and instruments. It also provides self-tests; self-measurement products, including thermometers, oxymeters, and blood pressure monitors; and oral care and medical aid products. The company provides its products to biology and medical analysis laboratories, hospitals, pharmacies, hyper and supermarkets, etc. It also exports its products internationally. The company was founded in 1993 and is based in Illkirch-Graffenstaden, France.
French Market Performance
- 7 Days: -2.6%
- 3 Months: -1.7%
- 1 Year: 5.2%
- Year to Date: 1.6%
Over the last 7 days, the market has dropped 2.6%, driven by a pullback of 7.6% in the Consumer Discretionary sector. As for the longer term, the market has actually risen by 5.2% in the last year. As for the next few years, earnings are expected to grow by 12% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading